Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

146 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
H2S-Prdx4 axis mitigates Golgi stress to bolster tumor-reactive T cell immunotherapeutic response.
Oberholtzer N, Chakraborty P, Kassir MF, Dressman J, Das S, Mills S, Comte-Walters S, Gooz M, Choi S, Parikh RY, Hedley Z, Vaena S, DeMass R, Scurti G, Romeo M, Gangaraju VK, Berto S, Hill E, Ball LE, Mehta AS, Maldonado EN, Nishimura MI, Ogretmen B, Mehrotra S. Oberholtzer N, et al. Among authors: ogretmen b. Sci Adv. 2024 Nov 15;10(46):eadp1152. doi: 10.1126/sciadv.adp1152. Epub 2024 Nov 15. Sci Adv. 2024. PMID: 39546607 Free PMC article.
A First-in-Human Phase I Study of BXQ-350, a First-in-Class Sphingolipid Metabolism Regulator, in Patients with Advanced/Recurrent Solid Tumors or High-Grade Gliomas.
Rixe O, Villano JL, Wesolowski R, Noonan AM, Puduvalli VK, Wise-Draper TM, Curry R 3rd, Yilmaz E, Cruze C, Ogretmen B, Tapolsky G, Takigiku R. Rixe O, et al. Among authors: ogretmen b. Clin Cancer Res. 2024 Nov 15;30(22):5053-5060. doi: 10.1158/1078-0432.CCR-24-1721. Clin Cancer Res. 2024. PMID: 39264252 Clinical Trial.
Alterations of ceramide synthesis induce PD-L1 internalization and signaling to regulate tumor metastasis and immunotherapy response.
Wofford W, Kim J, Kim D, Janneh AH, Lee HG, Atilgan FC, Oleinik N, Kassir MF, Saatci O, Chakraborty P, Tokat UM, Gencer S, Howley B, Howe P, Mehrotra S, Sahin O, Ogretmen B. Wofford W, et al. Among authors: ogretmen b. Cell Rep. 2024 Aug 27;43(8):114532. doi: 10.1016/j.celrep.2024.114532. Epub 2024 Jul 23. Cell Rep. 2024. PMID: 39046874 Free PMC article.
Targeting LINC00152 activates cAMP/Ca2+/ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancer.
Saatci O, Alam R, Huynh-Dam KT, Isik A, Uner M, Belder N, Ersan PG, Tokat UM, Ulukan B, Cetin M, Calisir K, Gedik ME, Bal H, Sener Sahin O, Riazalhosseini Y, Thieffry D, Gautheret D, Ogretmen B, Aksoy S, Uner A, Akyol A, Sahin O. Saatci O, et al. Among authors: ogretmen b. Cell Death Dis. 2024 Jun 15;15(6):418. doi: 10.1038/s41419-024-06814-3. Cell Death Dis. 2024. PMID: 38879508 Free PMC article.
Opportunistic pathogen Porphyromonas gingivalis targets the LC3B-ceramide complex and mediates lethal mitophagy resistance in oral tumors.
Sheridan M, Chowdhury N, Wellslager B, Oleinik N, Kassir MF, Lee HG, Engevik M, Peterson Y, Pandruvada S, Szulc ZM, Yilmaz Ö, Ogretmen B. Sheridan M, et al. Among authors: ogretmen b. iScience. 2024 Apr 30;27(6):109860. doi: 10.1016/j.isci.2024.109860. eCollection 2024 Jun 21. iScience. 2024. PMID: 38779482 Free PMC article.
Targeting LINC00152 activates cAMP/Ca2+/ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancer.
Saatci O, Alam R, Huynh-Dam KT, Isik A, Uner M, Belder N, Ersan PG, Cetin M, Tokat UM, Gedik ME, Bal H, Sahin OS, Riazalhosseini Y, Thieffry D, Gautheret D, Ogretmen B, Aksoy S, Uner A, Akyol A, Sahin O. Saatci O, et al. Among authors: ogretmen b. bioRxiv [Preprint]. 2023 Nov 5:2023.11.05.565697. doi: 10.1101/2023.11.05.565697. bioRxiv. 2023. Update in: Cell Death Dis. 2024 Jun 15;15(6):418. doi: 10.1038/s41419-024-06814-3. PMID: 38496603 Free PMC article. Updated. Preprint.
146 results